Epitranscriptomic Therapies Global Market Report 2026

Description

Epitranscriptomic therapies are medical treatments that target chemical modifications on ribonucleic acid molecules, including messenger RNA and non-coding RNAs, to regulate gene expression without changing the underlying DNA sequence. These therapies aim to influence cellular functions and biological processes, providing potential solutions for cancer, genetic disorders, and other complex diseases.

The key types of epitranscriptomic therapies include small molecule inhibitors, ribonucleic acid-modifying enzymes, antisense oligonucleotides, and other therapy types. Small molecule inhibitors refer to chemical compounds designed to target specific RNA-modifying enzymes for therapeutic purposes. These therapies are administered via injectable, oral, and other routes of administration. The applications include cancer, neurological disorders, metabolic diseases, infectious diseases, and other applications, and the end users are hospitals, research institutes, pharmaceutical and biotechnology companies, and other end users.

Tariffs are influencing the epitranscriptomic therapies market by increasing costs of imported laboratory instruments, sequencing platforms, reagents, and specialized manufacturing equipment required for therapy development and clinical trials. Pharmaceutical and research organizations in North America and Europe are most affected due to dependence on imported biotech equipment, while Asia-Pacific faces cost pressure in scaling manufacturing capabilities. These tariffs are increasing research and development expenses and lengthening development timelines. However, they are also encouraging domestic biomanufacturing investments, localized supply chains, and strategic partnerships that strengthen long-term therapeutic innovation capacity.

The epitranscriptomic therapies market research report is one of a series of new reports from The Business Research Company that provides epitranscriptomic therapies market statistics, including epitranscriptomic therapies industry global market size, regional shares, competitors with a epitranscriptomic therapies market share, detailed epitranscriptomic therapies market segments, market trends and opportunities, and any further data you may need to thrive in the epitranscriptomic therapies industry. This epitranscriptomic therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The epitranscriptomic therapies market size has grown exponentially in recent years. It will grow from $1.56 billion in 2025 to $1.9 billion in 2026 at a compound annual growth rate (CAGR) of 21.6%. The growth in the historic period can be attributed to advancements in rna biology research, growing understanding of gene regulation mechanisms, expansion of oncology research programs, availability of advanced sequencing technologies, increase in translational medicine initiatives.

The epitranscriptomic therapies market size is expected to see exponential growth in the next few years. It will grow to $4.2 billion in 2030 at a compound annual growth rate (CAGR) of 21.9%. The growth in the forecast period can be attributed to increasing investments in rna-based therapeutics, rising demand for targeted cancer treatments, expansion of personalized medicine approaches, growing clinical trial activity in epitranscriptomics, increasing regulatory engagement for novel rna therapies. Major trends in the forecast period include increasing development of epitranscriptomic drug pipelines, growing use of rna modification profiling tools, expansion of combination epitranscriptomic therapies, rising integration of bioinformatics in therapy design, enhanced focus on precision medicine applications.

The increasing demand for personalized medicine is anticipated to drive the growth of the epitranscriptomic therapies market in the coming years. Personalized medicine refers to a medical approach that tailors healthcare decisions, treatments, and interventions to the unique characteristics of each patient, including their genetic profile, lifestyle, and environment. The increasing demand for personalized medicine is mainly driven by the growing prevalence of chronic and complex diseases, as personalized treatments can more effectively address individual patient needs and improve health outcomes. Personalized medicine supports epitranscriptomic therapies by customizing treatments according to an individual's specific RNA modification patterns, enhancing therapeutic effectiveness while minimizing the risk of adverse effects. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the increasing demand for personalized medicine is driving the growth of the epitranscriptomic therapies market.

Companies in the epitranscriptomic therapies market are focusing on adopting strategic partnerships to develop innovative RNA-modifying cancer therapies. Strategic partnerships are cooperative arrangements where organizations combine resources, knowledge, or strengths to pursue shared objectives that drive faster growth, lower operational risks, and enhance market competitiveness. For example, in January 2026, STORM Therapeutics Ltd., a UK-based biotechnology company, partnered with Alida Biosciences Inc., a US-based technology company, to advance cancer therapies targeting epitranscriptomic mechanisms. The collaboration focuses on integrating AlidaBio's EpiPlex and EpiScout platforms with STORM's clinical trials of STC-15, a first-in-class METTL3 inhibitor. This partnership aims to identify and validate m6A RNA modification biomarkers that can predict patient responses and optimize therapeutic strategies. The collaboration combines drug development with advanced RNA profiling, marking a major step forward in epitranscriptomic cancer therapies.

In June 2025, Synfini Inc., a US-based biotechnology company, partnered with O2nix Bio Inc. to co-develop novel cancer therapeutics targeting FTSJ1, a tRNA-modifying enzyme involved in metastatic cancer cell survival. This partnership aims to advance epitranscriptomic-based therapies by combining O2nix Bio's expertise in RNA epitranscriptomics and cancer metastasis biology with Synfini's AI-driven drug discovery platform that integrates computational design, automated synthesis, and testing. O2nix Bio Inc. is a US-based biotechnology company specializing in RNA biology and epitranscriptomic mechanisms underlying cancer metastasis.

Major companies operating in the epitranscriptomic therapies market are AstraZeneca PLC, GSK plc, Moderna Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Arrakis Therapeutics Inc., AIRNA Corporation, CD Genomics, ProQR Therapeutics N.V., Nimbus Therapeutics LLC, Envisagenics Inc., Skyhawk Therapeutics Inc., Avidity Biosciences Inc., STORM Therapeutics Ltd., Omega Therapeutics Inc., Korro Bio Inc., Accent Therapeutics Inc., Alida Biosciences Inc., and O2nix Bio.

North America was the largest region in the epitranscriptomic therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epitranscriptomic therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the epitranscriptomic therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The epitranscriptomic therapies market consists of revenues earned by entities by providing services such as research and development services, contract research organization services, clinical trial services, epitranscriptomic profiling services, bioinformatics and data analysis services, regulatory and consulting services and manufacturing, and process development services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Epitranscriptomic Therapies Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses epitranscriptomic therapies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for epitranscriptomic therapies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The epitranscriptomic therapies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

Markets Covered:1) By Therapy Type: Small Molecule Inhibitors; Ribonucleic Acid Modifying Enzymes; Antisense Oligonucleotides; Other Therapy Types
2) By Route of Administration: Injectable; Oral; Other Routes Of Administration
3) By Application: Cancer; Neurological Disorders; Metabolic Diseases; Infectious Diseases; Other Applications
4) By End-User: Hospitals; Research Institutes; Pharmaceutical And Biotechnology Companies; Other End-Users
Subsegments:
1) By Small Molecule Inhibitors: Methyltransferase Inhibitors; Demethylase Inhibitors; Reader Protein Inhibitors; Writer Enzyme Inhibitors; Eraser Enzyme Inhibitors
2) By Ribonucleic Acid Modifying Enzymes: Methyltransferase Enzymes; Demethylase Enzymes; Pseudouridine Synthase Enzymes; Adenosine Deaminase Enzymes; Cytidine Deaminase Enzymes
3) By Antisense Oligonucleotides: Gapmer Oligonucleotides; Splice Modulating Oligonucleotides; Translation Blocking Oligonucleotides; Exon Skipping Oligonucleotides; Gene Expression Silencing Oligonucleotides
4) By Other Therapy Types: Ribonucleic Acid Interference Based Therapies; Messenger Ribonucleic Acid Editing Therapies; Epitranscriptomic Vaccine Platforms; Gene Regulation Modulation Therapies; Combination Epitranscriptomic Therapies
Companies Mentioned: AstraZeneca PLC; GSK plc; Moderna Inc.; Alnylam Pharmaceuticals Inc.; Ionis Pharmaceuticals Inc.; Arcturus Therapeutics Holdings Inc.; Arrakis Therapeutics Inc.; AIRNA Corporation; CD Genomics; ProQR Therapeutics N.V.; Nimbus Therapeutics LLC; Envisagenics Inc.; Skyhawk Therapeutics Inc.; Avidity Biosciences Inc.; STORM Therapeutics Ltd.; Omega Therapeutics Inc.; Korro Bio Inc.; Accent Therapeutics Inc.; Alida Biosciences Inc.; and O2nix Bio.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Product Code: PH4METHE01_G26Q1

1. Executive Summary

1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market

2. Epitranscriptomic Therapies Market Characteristics

2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global Epitranscriptomic Therapies Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation
2.4.5. Strategic Implications and Recommendations

3. Epitranscriptomic Therapies Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem
3.2. List Of Key Raw Materials, Resources & Suppliers
3.3. List Of Major Distributors and Channel Partners
3.4. List Of Major End Users

4. Global Epitranscriptomic Therapies Market Trends And Strategies

4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Artificial Intelligence & Autonomous Intelligence
- 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.4 Industry 4.0 & Intelligent Manufacturing
- 4.1.5 Sustainability, Climate Tech & Circular Economy
4.2. Major Trends
- 4.2.1 Increasing Development Of Epitranscriptomic Drug Pipelines
- 4.2.2 Growing Use Of Rna Modification Profiling Tools
- 4.2.3 Expansion Of Combination Epitranscriptomic Therapies
- 4.2.4 Rising Integration Of Bioinformatics In Therapy Design
- 4.2.5 Enhanced Focus On Precision Medicine Applications

5. Epitranscriptomic Therapies Market Analysis Of End Use Industries

5.1 Hospitals
5.2 Research Institutes
5.3 Pharmaceutical Companies
5.4 Biotechnology Companies
5.5 Contract Research Organizations

6. Epitranscriptomic Therapies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Epitranscriptomic Therapies Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Epitranscriptomic Therapies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Epitranscriptomic Therapies Market Size, Comparisons And Growth Rate Analysis
7.3. Global Epitranscriptomic Therapies Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Epitranscriptomic Therapies Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Epitranscriptomic Therapies Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Epitranscriptomic Therapies Market Segmentation

9.1. Global Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Small Molecule Inhibitors, Ribonucleic Acid Modifying Enzymes, Antisense Oligonucleotides, Other Therapy Types
9.2. Global Epitranscriptomic Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Injectable, Oral, Other Routes Of Administration
9.3. Global Epitranscriptomic Therapies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Cancer, Neurological Disorders, Metabolic Diseases, Infectious Diseases, Other Applications
9.4. Global Epitranscriptomic Therapies Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospitals, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users
9.5. Global Epitranscriptomic Therapies Market, Sub-Segmentation Of Small Molecule Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Methyltransferase Inhibitors, Demethylase Inhibitors, Reader Protein Inhibitors, Writer Enzyme Inhibitors, Eraser Enzyme Inhibitors
9.6. Global Epitranscriptomic Therapies Market, Sub-Segmentation Of Ribonucleic Acid Modifying Enzymes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Methyltransferase Enzymes, Demethylase Enzymes, Pseudouridine Synthase Enzymes, Adenosine Deaminase Enzymes, Cytidine Deaminase Enzymes
9.7. Global Epitranscriptomic Therapies Market, Sub-Segmentation Of Antisense Oligonucleotides, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Gapmer Oligonucleotides, Splice Modulating Oligonucleotides, Translation Blocking Oligonucleotides, Exon Skipping Oligonucleotides, Gene Expression Silencing Oligonucleotides
9.8. Global Epitranscriptomic Therapies Market, Sub-Segmentation Of Other Therapy Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Ribonucleic Acid Interference Based Therapies, Messenger Ribonucleic Acid Editing Therapies, Epitranscriptomic Vaccine Platforms, Gene Regulation Modulation Therapies, Combination Epitranscriptomic Therapies

10. Epitranscriptomic Therapies Market Regional And Country Analysis

10.1. Global Epitranscriptomic Therapies Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Epitranscriptomic Therapies Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Epitranscriptomic Therapies Market

11.1. Asia-Pacific Epitranscriptomic Therapies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Epitranscriptomic Therapies Market

12.1. China Epitranscriptomic Therapies Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Epitranscriptomic Therapies Market

13.1. India Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Epitranscriptomic Therapies Market

14.1. Japan Epitranscriptomic Therapies Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Epitranscriptomic Therapies Market

15.1. Australia Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Epitranscriptomic Therapies Market

16.1. Indonesia Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Epitranscriptomic Therapies Market

17.1. South Korea Epitranscriptomic Therapies Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Epitranscriptomic Therapies Market

18.1. Taiwan Epitranscriptomic Therapies Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Epitranscriptomic Therapies Market

19.1. South East Asia Epitranscriptomic Therapies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Epitranscriptomic Therapies Market

20.1. Western Europe Epitranscriptomic Therapies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Epitranscriptomic Therapies Market

21.1. UK Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Epitranscriptomic Therapies Market

22.1. Germany Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Epitranscriptomic Therapies Market

23.1. France Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Epitranscriptomic Therapies Market

24.1. Italy Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Epitranscriptomic Therapies Market

25.1. Spain Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Epitranscriptomic Therapies Market

26.1. Eastern Europe Epitranscriptomic Therapies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Epitranscriptomic Therapies Market

27.1. Russia Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Epitranscriptomic Therapies Market

28.1. North America Epitranscriptomic Therapies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Epitranscriptomic Therapies Market

29.1. USA Epitranscriptomic Therapies Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Epitranscriptomic Therapies Market

30.1. Canada Epitranscriptomic Therapies Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Epitranscriptomic Therapies Market

31.1. South America Epitranscriptomic Therapies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Epitranscriptomic Therapies Market

32.1. Brazil Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Epitranscriptomic Therapies Market

33.1. Middle East Epitranscriptomic Therapies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Epitranscriptomic Therapies Market

34.1. Africa Epitranscriptomic Therapies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Epitranscriptomic Therapies Market, Segmentation By Therapy Type, Segmentation By Route of Administration, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Epitranscriptomic Therapies Market Regulatory and Investment Landscape

36. Epitranscriptomic Therapies Market Competitive Landscape And Company Profiles

36.1. Epitranscriptomic Therapies Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Epitranscriptomic Therapies Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
36.3. Epitranscriptomic Therapies Market Company Profiles
- 36.3.1. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. GSK plc Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. Alnylam Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. Ionis Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Epitranscriptomic Therapies Market Other Major And Innovative Companies

Arcturus Therapeutics Holdings Inc., Arrakis Therapeutics Inc., AIRNA Corporation, CD Genomics, ProQR Therapeutics N.V., Nimbus Therapeutics LLC, Envisagenics Inc., Skyhawk Therapeutics Inc., Avidity Biosciences Inc., STORM Therapeutics Ltd., Omega Therapeutics Inc., Korro Bio Inc., Accent Therapeutics Inc., Alida Biosciences Inc., O2nix Bio

38. Global Epitranscriptomic Therapies Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Epitranscriptomic Therapies Market

41. Epitranscriptomic Therapies Market High Potential Countries, Segments and Strategies

41.1 Epitranscriptomic Therapies Market In 2030 - Countries Offering Most New Opportunities
41.2 Epitranscriptomic Therapies Market In 2030 - Segments Offering Most New Opportunities
41.3 Epitranscriptomic Therapies Market In 2030 - Growth Strategies
- 41.3.1 Market Trend Based Strategies
- 41.3.2 Competitor Strategies

42. Appendix

42.1. Abbreviations
42.2. Currencies
42.3. Historic And Forecast Inflation Rates
42.4. Research Inquiries
42.5. The Business Research Company
42.6. Copyright And Disclaimer